Skip to main content

Table 7 Percentage of responding panel members (N = 6) who recommended that treatment should be initiated, based on evaluation of each case history against PREDICT-FD criteria, EFWG guidance, and their own country’s guidelines

From: Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?

Case

PREDICT-FD

EFWG

Country

Case

PREDICT-FD

EFWG

Country

1

3 (60)

2 (50)

3 (60)

10

2 (50)

1 (25)

2 (40)

2

4 (100)

4 (100)

4 (100)

11

2 (67)

2 (67)

3 (75)

3

3 (100)

1 (33)

1 (33)

12

2 (67)

3 (100)

4 (100)

4

3 (100)

3 (100)

3 (100)

13

2 (100)

2 (100)

4 (100)

5

2 (67)

2 (67)

2 (67)

14

3 (100)

3 (100)

4 (100)

6

3 (100)

3 (100)

4 (100)

15

2 (100)

2 (100)

2 (67)

7

2 (100)

2 (100)

3 (100)

16

2 (100)

2 (100)

3 (100)

8

1 (33)

1 (33)

1 (25)

17

2 (100)

2 (100)

3 (100)

9

1 (50)

1 (50)

2 (67)

    
  1. Data are n (%). Shaded rows indicate cases for which disease-specific therapy initiation was recommended unanimously, irrespective of which set of guidelines was used
  2. EFWG, European Fabry Working Group; PREDICT-FD, PRoposing Early Disease Indicators for Clinical Tracking in Fabry Disease